左西孟旦治疗急性心肌梗死并心力衰竭患者的疗效观察

Clinical Observation on Levosimendan in the Treatment of Patients With Acute Myocardial Infarction Complicated With Heart Failure

目的观察急性ST段抬高型心肌梗死并心力衰竭(心衰)患者使用左西孟旦后的临床治疗效果。方法选择2018年1—6月本院108例行急诊PCI后的急性ST段抬高型心肌梗死并心力衰竭患者,根据治疗途径的差异将其划分为对照组和观察组,前者接受心梗后心衰常规治疗,后者在常规治疗的同时选择左西孟旦进行联合治疗。结果接受治疗后,观察组总有效率为96.64%,高于对照组的78.84%(P<0.05);观察组治疗后LVEF高于对照组;两组治疗后NT-proBNP水平均下降,观察组为(620.5±115.0)pg/ml,对照组为(812.3±120.4)pg/ml,观察组较对照组下降更明显。以上数据,对照组与观察组对比,差异均具有统计学意义(P <0.05)。结论针对ST段抬高型心肌梗死并心力衰竭患者,选择左西孟旦进行治疗能够取得良好效果。

Objective To observe the effect of levosimendan on the patients with ST segment elevation myocardial infarction(STEMI)complicated with heart failure(HF).Methods From January to June 2018,108 patients with acute ST-segment elevation myocardial infarction complicated with heart failure who underwent emergency PCI were divided into control group and observation group according to different treatment approaches.The control group were treated with traditional anti-heart failure treatment.The observation group were treated with levosimendan on the basis of the treatment in the control group.Results After treatment,the total effective rate of the observation group was 96.64%,which was higher than 78.84%of the control group(P<0.05).The LVEF of the observation group after treatment was higher than that of the control group.After treatment,NTproBNP levels in both groups decreased,the observation group was(620.5±115.0)pg/ml,and the control group was(812.3±120.4)pg/ml.The observation group was significantly lower than the control group.The difference between the control group and the observation group was statistically significant(P<0.05).Conclusion Levosimendan has very favorabl eeficacy for the patients with heart failure combined with acute STelevation myocardium infarction.